CClinicalTrials.gg
RecruitingNCT07568626Updated Jul 14, 2026

Factors for Prolonged Hospital Stays in Patients Undergoing ERCP

An observational study in Post-ERCP Adverse Events and ERCP Complications, sponsored by Air Force Military Medical University, China. Recruiting at 5 sites in China. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Air Force Military Medical University, China · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
504
Ages
65 Years and older
Sex
All
01

Study summary

Endoscopic retrograde cholangiopancreatography (ERCP) is a crucial minimally invasive technique for the diagnosis and treatment of biliary and pancreatic diseases. However, it remains technically demanding and carries a postoperative adverse event (AE) rate exceeding 10% (e.g., pancreatitis, bleeding, and perforation), which subsequently leads to prolonged length of stay (LOS) and increased healthcare costs. With the rapid acceleration of population aging, the clinical demand for ERCP among the elderly has surged. Although ERCP is generally considered safe for older adults, advanced age also increases the risk of ERCP-related AEs and prolonged LOS. While previous studies investigated the outcomes of ERCP in elderly patients, those studies were predominantly retrospective, accompanied by selection bias. Moreover, insufficient factors were included in those retrospective studies. Importantly, some aging-related parameters, such as frailty, functional reserve, cognitive and psychological status, were not included in previous studies. Therefore, the investigators conducted a prospective, multicenter cohort study aimed at investigating outcomes in elderly patients undergoing ERCP and comprehensive factors (patient-related, procedure-related, and geriatric factors) associated with adverse outcomes.

02

Conditions studied

  • Post-ERCP Adverse Events
  • ERCP Complications

Keywords

  • Elderly
  • Length of Stay
  • Adverse Events
  • ERCP
03

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients aged ≥ 65 years old who are scheduled to undergo endoscopic retrograde cholangiopancreatography (ERCP) are eligible for our study.

Inclusion criteria

  1. Patient age ≥ 65 years
  2. Scheduled to undergo ERCP procedure

Exclusion criteria

Exclusion Criteria:

  1. Severe cognitive dysfunction
  2. Severe hearing impairment
  3. Known or suspected gastrointestinal perforation
  4. Hemodynamic instability
  5. Pregnant or lactating women
  6. Unable to sign the informed consent form
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
504 participants (estimated)
Patient registry
No
05

What researchers measure

Primary outcomes

  1. Prolonged Postoperative Length of Stay

    A binary outcome defined as a postoperative length of stay \> 5 days. It is calculated as the duration from the completion of the ERCP procedure to the date of formal hospital discharge.

    Time frame: 30 days

Secondary outcomes

  1. Rate of total adverse events

    Adverse events include ERCP-related or non ERCP-related adverse events

    Time frame: 30 days

  2. Total Length of Hospital Stay

    Total length of stay (TLOS), defined as the total duration in days from the date of hospital admission to the date of hospital discharge.

    Time frame: 30 days

  3. Post-procedure Length of Hospital Stay

    The number of days from the day of the ERCP procedure to hospital discharge

    Time frame: 30 days

  4. Rate of post-ERCP Pancreatitis

    a new or aggravated upper abdominal pain, with an elevated pancreatic enzyme of at least 3 times as the upper limit of normal value 24h after procedure and prolonged hospitalization days for at least 2 days. This definition was based on a widely recognized Cotton consensus.

    Time frame: 30 days

  5. Rate of ERCP-related bleeding

    Bleeding was established according to Cotton criteria. Mild: a documented decrease in hemoglobin concentration by \<3 g/L, without requiring the blood transfusion; Moderate: blood transfusion ≤ 4 units; without need for angiographic or surgery interventions ;Severe: Transfusion: ≥ 5 units or requiring for angiographic or surgery interventions.

    Time frame: 30 days

  6. Rate of ERCP-related perforation

    Perforation was established according to Cotton criteria.Mild: slight leakage of fluid or contrast dye, manageable through fluid administration and suction therapy 3 days; Moderate: definite perforation required to be managed for 4-10 days; Severe: management for more than 10 days or requiring for percutaneous or surgical intervention.

    Time frame: 30 days

  7. Rate of ERCP-related infection

    Infection was established according to Cotton criteria.Mild: temperature \>38℃ for 24-48h; Moderate: Febrile illness requiring \>3 days of hospital treatment; endoscopic or percutaneous interventions; Severe: septic shock or requiring surgery.

    Time frame: 30 days

  8. Total Hospitalization Costs

    The sum of all medical expenses incurred during the entire hospitalization, denominated in Chinese Yuan (CNY). This includes costs for medication, laboratory and imaging tests, treatments, procedures, surgical operations, medical supplies, and bed occupancy.

    Time frame: 30 days

06

Study locations

5 of 5 sites recruiting
  • Xiamen Hong'ai Hospital
    Xiamen, Fujian 361009, China
    Recruiting
  • Xijing Hospital of Digestive Diseases
    Xi'an, Shaanxi 710000, China
    Recruiting
  • The Second Affiliated Hospital of Air Force Military Medical University
    Xi'an, Shaanxi 710038, China
    Recruiting
  • Department of Gastroenterology, 986 Hospital of Xijing Hospital, Fourth MilitaryMedical University
    Xi'an, Shaanxi 710054, China
    Recruiting
  • Xi'an Honghui Hospital
    Xi'an, Shaanxi 710054, China
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07568626
Lead sponsor
Air Force Military Medical University, China
Responsible party
Yanglin Pan (Professor, Air Force Military Medical University, China) — Principal investigator
First posted
May 6, 2026
Start date
Feb 15, 2026
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Jul 14, 2026

Study contacts

Yanglin Pan, M.D
Contact
yanglinpan@hotmail.com
13991811225

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion